New pill takes on brain tumors and metastases in early trial

NCT ID NCT06047379

Recruiting now Disease control Sponsor: Neonc Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) astrocytoma, IDH-mutant, grade 2 brain cancer central nervous system cancer cervical cancer colorectal cancer colorectal neoplasm cutaneous neuroendocrine carcinoma diffuse astrocytoma esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma glioblastoma head and neck squamous cell carcinoma IDH-wildtype glioblastoma Lynch syndrome melanoma metastatic malignant neoplasm in the brain mismatch repair cancer syndrome non-small cell lung carcinoma renal cell carcinoma small cell lung carcinoma squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES, ADULT CERVICAL CANCER COLORECTAL CANCER DIFFUSE ASTROCYTOMA, IDH-MUTANT ESOPHAGEAL CANCER ESOPHAGEAL SQUAMOUS CELL CARCINOMA GASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA GLIOBLASTOMA, IDH-WILDTYPE HEAD AND NECK SQUAMOUS CELL CARCINOMA MELANOMA MERKEL CELL CARCINOMA MICROSATELLITE INSTABILITY-HIGH COLORECTAL CANCER MICROSATELLITE INSTABILITY-HIGH SOLID MALIGNANT TUMOR MISMATCH REPAIR DEFICIENT COLORECTAL CANCER MISMATCH REPAIR DEFICIENT SOLID MALIGNANT TUMOR NON-SMALL CELL LUNG CANCER RENAL CELL CARCINOMA SMALL CELL LUNG CANCER SQUAMOUS CELL CARCINOMA UROTHELIAL CARCINOMA

Contacts and locations

Locations

Baylor, Scott and White Research Institute
RECRUITING

Dallas, Texas, 75246, United States
MDR Core Network
RECRUITING

Boynton Beach, Florida, 33426, United States
Northwest Medical Specialties
RECRUITING

Tacoma, Washington, 98405, United States
OPN Healthcare, Inc
RECRUITING

Glendale, California, 91203, United States
Precision NextGen Oncology
RECRUITING

Beverly Hills, California, 90212, United States
University of Southern California
RECRUITING

Los Angeles, California, 90033, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.